Coherus Biosciences Inc (CHRS) Shares Rise Despite Market Challenges

Coherus Biosciences Inc (NASDAQ: CHRS) has experienced a rise in its stock price by 5.70 compared to its previous closing price of 1.47. However, the company has seen a fall of -4.09% in its stock price over the last five trading days. globenewswire.com reported 2024-12-18 that – Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer –

Is It Worth Investing in Coherus Biosciences Inc (NASDAQ: CHRS) Right Now?

Company’s 36-month beta value is 0.81.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”

The public float for CHRS is 110.59M, and currently, short sellers hold a 27.77% ratio of that floaft. The average trading volume of CHRS on January 14, 2025 was 5.02M shares.

CHRS’s Market Performance

CHRS’s stock has seen a -4.09% decrease for the week, with a -5.83% drop in the past month and a 56.92% gain in the past quarter. The volatility ratio for the week is 7.08%, and the volatility levels for the past 30 days are at 9.79% for Coherus Biosciences Inc The simple moving average for the past 20 days is 1.54% for CHRS’s stock, with a 3.25% simple moving average for the past 200 days.

Analysts’ Opinion of CHRS

Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the previous year 2024.

Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.

CHRS Trading at 21.29% from the 50-Day Moving Average

After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.68% of loss for the given period.

Volatility was left at 9.79%, however, over the last 30 days, the volatility rate increased by 7.08%, as shares surge +5.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +110.69% upper at present.

During the last 5 trading sessions, CHRS fell by -2.47%, which changed the moving average for the period of 200-days by -34.71% in comparison to the 20-day moving average, which settled at $1.5315. In addition, Coherus Biosciences Inc saw 12.59% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for CHRS

Current profitability levels for the company are sitting at:

  • -0.43 for the present operating margin
  • 0.43 for the gross margin

The net margin for Coherus Biosciences Inc stands at -0.0. The total capital return value is set at -0.63.

Based on Coherus Biosciences Inc (CHRS), the company’s capital structure generated 1.61 points at debt to capital in total, while cash flow to debt ratio is standing at -0.27. The debt to equity ratio resting at -2.63. The interest coverage ratio of the stock is -4.04.

Currently, EBITDA for the company is -193.94 million with net debt to EBITDA at -1.23. When we switch over and look at the enterprise to sales, we see a ratio of 1.03. The receivables turnover for the company is 1.53for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.

Conclusion

In a nutshell, Coherus Biosciences Inc (CHRS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts